Relmada Therapeutics (RLMD) Cash from Operations (2012 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Cash from Operations of 15067488.0 for Q1 2026, up 16.6% year-over-year from 12922117.82 in Q1 2025, and down 3.23% quarter-over-quarter from 14596223.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Cash from Operations (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Cash from Operations for 15 consecutive years, with 15067488.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 16.6% year-over-year to 15067488.0; the TTM figure through Mar 2026 stood at 42787443.0 (up 24.65% YoY), while the FY2025 annual figure was 45786988.0, up 11.53% from the prior year.
- Cash from Operations slipped to 15067488.0 in Q1 2026 per RLMD's latest filing, from 14596223.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 6401876.0 in Q2 2025 and bottomed at 35882900.0 in Q4 2022.
- Historically, Cash from Operations has averaged 15768888.06 across 5 years, with a median of 14596223.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 71.44% — and 2025, when it plunged 65.87%.
- Relmada Therapeutics' Cash from Operations stood at 35882900.0 in 2022, then jumped by 71.44% to 10249714.0 in 2023, then rose by 14.15% to 8799634.0 in 2024, then tumbled by 65.87% to 14596223.0 in 2025, then retreated by 3.23% to 15067488.0 in 2026.
- Business Quant data shows RLMD's Cash from Operations at 15067488.0 in Q1 2026, 14596223.0 in Q4 2025, and 6721856.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -9.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.61 Mn |
| Mar 31, 2026 | -15.07 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | -6.72 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -18.07 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -16.66 Mn |
| Jun 30, 2024 | -13.26 Mn |
| Mar 31, 2024 | -13.04 Mn |
| Dec 31, 2023 | -10.25 Mn |
| Sep 30, 2023 | -11.63 Mn |
| Jun 30, 2023 | -13.27 Mn |
| Mar 31, 2023 | -16.51 Mn |
| Dec 31, 2022 | -35.88 Mn |
| Sep 30, 2022 | -26.86 Mn |
| Jun 30, 2022 | -21.63 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -37.66 Mn |
| Sep 30, 2021 | -20.92 Mn |